Cheryl Gault is COO at Rapport Therapeutics, Inc. (RAPP). They have made 1 open-market trade across 1 company since 2025, most recently 2026-06-30.
CIK 0001839046
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RAPP | 149,914 | $4.1M |
Shares reported on the most recent Form 4, priced at the 2026-07-01 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RAPP | SELL · 10b5-1 | 2026-06-30 | 2026-07-01 | $41.58 | $416K | +2.7% | +2.0% | -17.9% |
| RAPP | SELL · 10b5-1 | 2026-03-30 | 2026-03-31 | $28.19 | $564K | +10.4% | +5.6% | +29.0% |
| RAPP | SELL | 2026-03-05 | 2026-03-09 | $28.93 | $58K | -6.0% | +15.4% | +25.9% |
| RAPP | SELL · 10b5-1 | 2025-11-26 | 2025-12-01 | $30.10 | $151K | +1.0% | +6.5% | -0.4% |
| RAPP | SELL · 10b5-1 | 2025-09-08 | 2025-09-10 | $38.33 | $192K | +16.8% | +18.6% | +28.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.